

- infarction heart failure. *Drug Des Devel Ther* 2018;**12**:3407–18. <https://doi.org/10.2147/DDDT.S182834>
30. Yang H-J, Kong B, Shuai W, Zhang J-J, Huang H. Shensong Yangxin protects against metabolic syndrome-induced ventricular arrhythmias by inhibiting electrical remodeling. *Front Pharmacol* 2020;**11**:993. <https://doi.org/10.3389/fphar.2020.00993>
31. Zhao H-Y, Zhang S-D, Zhang K, Wang X, Zhao Q-Y, Zhang S-J, et al. Effect of Shensong Yangxin on the progression of paroxysmal atrial fibrillation is correlated with regulation of autonomic nerve activity. *Chin Med J (Engl)* 2017;**130**:171–8. <https://doi.org/10.4103/0366-6999.197997>
32. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J* 2021;**42**:373–498. <https://doi.org/10.1093/eurheartj/ehaa612>
33. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2024;**83**:109–279. <https://doi.org/10.1016/j.jacc.2023.08.017>

Correction

<https://doi.org/10.1093/eurheartj/ehae594>

Online publish-ahead-of-print 20 September 2024

Correction to: Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy

This is a correction to: Daniel Gaudet, Susanne Greber-Platzer, Laurens F. Reeskamp, Gabriella Iannuzzo, Robert S. Rosenson, Samir Saheb, Claudia Stefanutti, Erik Stroes, Albert Wiegman, Traci Turner, Shazia Ali, Poulabi Banerjee, Tiera Drewery, Jennifer McGinniss, Alpana Waldron, Richard T. George, Xue-Qiao Zhao, Robert Pordy, Jian Zhao, Eric Bruckert, and Frederick J. Raal, Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy, *European Heart Journal*, Volume 45, Issue 27, 14 July 2024, Pages 2422–2434, <https://doi.org/10.1093/eurheartj/ehae325>

The originally published version of this manuscript contained the following sentence: “Recent European Society of Cardiology and European Atherosclerosis Society guidelines for patients with HoFH recommend LDL-C levels of <2.5 mmol/L (<100 mg/dL) and <1.8 mmol/L (<70 mg/dL) for adults with and without ASCVD, respectively.” This has been corrected online to: “Recent European Society of Cardiology and European Atherosclerosis Society guidelines for patients with HoFH recommend LDL-C levels of <1.8 mmol/L (<70 mg/dL) and <1.4 mmol/L (<55 mg/dL) for adults with and without ASCVD, respectively.”

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.